ArticleFrontiers in pharmacology2026
Comparison of CYP2C9 activity between Ethiopian and non-Ethiopian Jews: an interethnic study of (
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: CYP2C9 is characterized by marked interindividual variability. A significant fraction of this variability is attributed to ethnic specific genetic polymorphisms. We have recently shown that the activity of CYP2C9 as measured by phenytoin metabolic ratio is decreased by 30% among Ethiopians as compared to non-Ethiopians Jews carriers of CYP2C9*1/*1 genotype. The purpose of the current study was to evaluate whether similar difference exists in the pharmacokinetics of (S)-warfarin, a prototype substrate of CYP2C9. Validating this systemic reduction through robust Methods: Single dose of warfarin (20 mg) was administered to 150 Ethiopians and 180 non-Ethiopian healthy, non-smokers subjects. CYP2C9 activity was assessed by (S)-warfarin oral clearance and INR was monitored for 120 h post-dose. CYP2C9 genotyping was performed by direct sequencing. Results: CYP2C9 genotype correlated with the (S)-warfarin oral clearance in both ethnic groups (p < 0.001). Despite the predominance of CYP2C9*1/*1 genotype in the Ethiopian group, (S)-warfarin oral clearance was reduced by 12.3% as compared to the non-Ethiopian (p < 0.001). Comparison limited to carriers of CYP2C9*1/*1 genotype yielded higher difference of 15.3% (p < 0.001). Stratified VKORC1 genotype analysis revealed significantly greater pharmacodynamic effect in Ethiopians as compared to non-Ethiopians carrying VKORC1 AB and BB haplotypes (AUCINR120: p < 0.04 and p < 0.004 respectively; INRMAX: p < 0.03 and p < 0.002, respectively). Conclusion: CYP2C9 activity is modestly reduced in Ethiopians as compared to non-Ethiopians thus corroborating our findings regrading phenytoin metabolism. Ethiopian Jews may be susceptible to experience adverse effects when administered CYP2C9 substrate characterized by a narrow therapeutic window. The cause for decreased CYP2C9 activity in Ethiopians is currently under investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.